Deep Genomics Strengthens Momentum with Latest Executive Hires

Cambridge, MA/Toronto CA – April 14, 2025 – Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic R&D with its AI foundation models platform, today announced two key executive hires joining the team amidst continued growth.  

• Monika Kowalczyk, MD, PhD, joins as Vice President of Platform Technology, bringing extensive expertise in clinical medicine and genomics research to Deep Genomics. In her former role as Head of Systems Biology at Decibel Therapeutics, she contributed to development of DB-OTO – a groundbreaking investigational gene therapy that significantly improved hearing levels for children facing a rare genetic disease. Kowalczyk will lead the advancement of Deep Genomics’ next-generation sequencing, genomics, molecular biology and cellular technology capabilities while closely collaborating with machine learning and engineering departments for seamless integration into the AI foundation models platform. 
• Shawdee Eshghi, PhD, joins as Vice President of Platform Biology. She joins Deep Genomics from Gingko Bioworks, where she helped lead the genetic medicine team from its inception to partnering with leading biotech and pharmaceutical companies on high throughput screening projects in cell therapy, gene editing, iPSC engineering and RNA therapeutics. Eshghi will lead all data generation and therapeutic discovery activities at Deep Genomics, helping to advance both the strength of its platform with proprietary data, and using it to generate drugs for patients in need.

“Monika and Shawdee are two brilliant minds with a wealth of knowledge in genomics and drug development that will undoubtedly propel Deep Genomics to new heights in TechBio,” said Dr. Brendan Frey, Founder and CIO of Deep Genomics. “We are honored to have them join our leadership team and help make possible new levels of untold productivity through AI across both our Cambridge and Toronto offices.”  

Deep Genomics’ continued expansion has been made possible by its groundbreaking impact in the realm of genomic R&D. The company was recently named BioTechnology Company of the Year for the Stevie® Awards, in recognition of its cutting-edge AI foundation model, BigRNA, which is revolutionizing the decoding of RNA biology and the development of life-changing medicine.  

Poised for additional growth, Deep Genomics invites talent interested in pioneering work at the intersection of genomics, drug development, and AI to visit the careers page on their website at https://www.deepgenomics.com/careers/. 

About Deep Genomics: 

Deep Genomics is a multidisciplinary team of AI and biology scientists dedicated to pioneering a new era of genomic research and development through its BigRNA - the first AI foundation model for decoding RNA biology and designing therapeutics. Leveraging cutting-edge AI technologies and biological insights, Deep Genomics is at the forefront of revolutionizing drug discovery and development. Through its innovative approach and collaborative partnerships, Deep Genomics aims to accelerate the delivery of life-saving therapeutics to patients worldwide. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow us on LinkedIn and Twitter. 

Media Contact

Mandy Mellinger 

Fight or Flight 

deepgenomics@fightorflight.com

###